TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF NASAL SPRAY MARKET 21
1.4 CURRENCY AND PRICING 22
1.5 LIMITATION 22
1.6 MARKETS COVERED 22
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHIC SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 RESEARCH METHODOLOGY 28
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.7 SECONDARY SOURCES 32
2.8 ASSUMPTIONS 32
3 MARKET OVERVIEW 33
3.1 DRIVERS 35
3.1.1 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 35
3.1.2 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 36
3.1.3 INCREASE IN INFECTION & ALLERGIC CASES 37
3.2 RESTRAINTS 37
3.2.1 PRODUCT RECALLS 37
3.3 OPPORTUNITIES 38
3.3.1 NEW RISING DEMAND FOR SELF ADMINISTRATIVE DRUG DELIVERY 38
3.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 38
3.4 CHALLENGES 39
3.4.1 REGULATORY HURDLES 39
4 EXECUTIVE SUMMARY 40
5 PREMIUM INSIGHTS 43
?
6 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE 46
6.1 OVERVIEW 47
6.2 DECONGESTION NASAL SPRAY 49
6.3 SALT WATER SOLUTION/ SALINE NASAL SPRAY 50
6.4 STEROID NASAL SPRAY 52
6.5 OTHERS 53
7 ASIA-PACIFIC N ASAL SPRAY MARKET, BY CONTAINER DESIGN 54
7.1 OVERVIEW 55
7.2 PRESSURIZED CANISTERS 57
7.3 PUMP BOTTLES 58
8 ASIA-PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM 59
8.1 OVERVIEW 60
8.2 UNIT/SINGLE DOSE 62
8.3 BI DOSE 64
8.4 MULTI DOSE 65
9 ASIA-PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 67
9.1 OVERVIEW 68
9.2 ANTIHISTAMINE 70
9.3 NASAL STEROIDS 72
9.4 MAST CELL INHIBITOR 73
9.5 ANTICHOLINERGIC 74
10 ASIA-PACIFIC NASAL SPRAY MARKET, BY APPLICATION 75
10.1 OVERVIEW 76
10.2 ALLERGIC AND NON-ALLERGIC RHINITIS 78
10.3 NASAL CONGESTION 80
10.4 CENTRAL NERVOUS SYSTEM DISORDERS 81
10.5 VACCINATION 82
10.6 OTHERS 83
11 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION MODE 84
11.1 OVERVIEW 85
11.2 PRESCRIPTION BASED 87
11.3 OVER THE COUNTER 88
?
12 ASIA-PACIFIC NASAL SPRAY MARKET, BY END USER 90
12.1 OVERVIEW 91
12.2 HOSPITALS 93
12.3 CLINICS 94
12.4 HOME CARE SETTINGS 95
12.5 COMMUNITY HEALTH CARE 96
13 ASIA-PACIFIC NASAL SPRAY MARKET, BY GEOGRAPHY 97
13.1 ASIA-PACIFIC 97
13.1.1 INCREAISNG PREVELENCE OF THE COPD 97
13.1.2 CHINA 106
13.1.3 JAPAN 110
13.1.4 INDIA 114
13.1.5 AUSTRALIA 118
13.1.6 SOUTH KOREA 122
13.1.7 MALAYSIA 126
13.1.8 THAILAND 130
13.1.9 SINGAPORE 134
13.1.10 INDONESIA 138
13.1.11 PHILIPPINES 142
13.1.12 REST OF ASIA PACIFIC 146
14 ASIA-PACIFIC NASAL SPRAY MARKET, COMPANY LANDSCAPE 147
14.1 COMPANY SHARE ANALYSIS; ASIA-PACIFIC 147
15 COMPANY PROFILE 148
15.1 PFIZER INC. 148
15.1.1 COMPANY OVERVIEW 148
15.1.2 REVENUE ANALYSIS 148
15.1.3 COMPANY SHARE ANALYSIS 149
15.1.4 PRODUCT PORTFOLIO 150
15.1.5 RECENT DEVELOPMENTS 150
15.2 CIPLA INC. 151
15.2.1 COMPANY OVERVIEW 151
15.2.2 REVENUE ANALYSIS 151
15.2.3 COMPANY SHARE ANALYSIS 152
15.2.4 PRODUCT PORTFOLIO 152
15.2.5 RECENT DEVELOPMENTS 153
?
15.3 BAYER AG 154
15.3.1 COMPANY OVERVIEW 154
15.3.2 REVENUE ANALYSIS 154
15.3.3 COMPANY SHARE ANALYSIS 155
15.3.4 PRODUCT PORTFOLIO 155
15.3.5 RECENT DEVELOPMENTS 155
15.4 INNOVUS PHARMACEUTICALS, INC. 156
15.4.1 COMPANY OVERVIEW 156
15.4.2 REVENUE ANALYSIS 156
15.4.3 COMPANY SHARE ANALYSIS 157
15.4.4 PRODUCT PORTFOLIO 157
15.4.5 RECENT DEVELOPMENTS 157
15.5 GLAXOSMITHKLINE PLC. 158
15.5.1 COMPANY OVERVIEW 158
15.5.2 REVENUE ANALYSIS 158
15.5.3 PRODUCT PORTFOLIO 159
15.5.4 RECENT DEVELOPMENTS 159
15.6 ADAPT PHARMA, INC. 160
15.6.1 COMPANY OVERVIEW 160
15.6.2 GEOGRAPHIC PRESENCE 160
15.6.3 PRODUCT PORTFOLIO 161
15.6.4 RECENT DEVELOPMENTS 161
15.7 AISHWARYA GROUP 162
15.7.1 COMPANY OVERVIEW 162
15.7.2 PRODUCT PORTFOLIO 162
15.7.3 RECENT DEVELOPMENTS 162
15.8 ALLERGAN 163
15.8.1 COMPANY OVERVIEW 163
15.8.2 REVENUE ANALYSIS 163
15.8.3 PRODUCT PORTFOLIO 163
15.8.4 RECENT DEVELOPMENTS 164
15.9 ARIUS FORMULATIONS PVT LTD 165
15.9.1 COMPANY OVERVIEW 165
15.9.2 PRODUCT PORTFOLIO 165
15.9.3 RECENT DEVELOPMENTS 165
15.10 AURENA 166
15.10.1 COMPANY OVERVIEW 166
15.10.2 GEOGRAPHIC PRESENCE 166
15.10.3 PRODUCT PORTFOLIO 167
15.10.4 RECENT DEVELOPMENTS 167
15.11 CATALENT, INC 168
15.11.1 COMPANY OVERVIEW 168
15.11.2 REVENUE ANALYSIS 168
15.11.3 PRODUCT PORTFOLIO 169
15.11.4 RECENT DEVELOPMENTS 169
15.12 EGALET CORPORATION 170
15.12.1 COMPANY OVERVIEW 170
15.12.2 REVENUE ANALYSIS 170
15.12.3 PRODUCT PORTFOLIO 171
15.12.4 RECENT DEVELOPMENTS 171
15.13 J PHARMACEUTICALS 172
15.13.1 COMPANY OVERVIEW 172
15.13.2 PRODUCT PORTFOLIO 172
15.13.3 RECENT DEVELOPMENTS 172
15.14 LEEFORD HEALTHCARE LTD 173
15.14.1 COMPANY OVERVIEW 173
15.14.2 GEOGRAPHIC PRESENCE 173
15.14.3 PRODUCT PORTFOLIO 174
15.14.4 RECENT DEVELOPMENTS 174
15.15 MYLAN N.V. 175
15.15.1 REVENUE ANALYSIS 175
15.15.2 PRODUCT PORTFOLIO 176
15.15.3 RECENT DEVELOPMENTS 176
15.16 SANDOZ INTERNATIONAL GMBH 177
15.16.1 COMPANY OVERVIEW 177
15.16.2 GEOGRAPHIC PRESENCE 177
15.16.3 PRODUCT PORTFOLIO 178
15.16.4 RECENT DEVELOPMENTS 178
15.17 ST. RENATUS 179
15.17.1 COMPANY OVERVIEW 179
15.17.2 PRODUCT PORTFOLIO 179
15.17.3 RECENT DEVELOPMENTS 179
15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD. 180
15.18.1 COMPANY OVERVIEW 180
15.18.2 REVENUE ANALYSIS 180
15.18.3 PRODUCT PORTFOLIO 181
15.18.4 RECENT DEVELOPMENTS 181
?
15.19 ULTRATECH INDIA LIMITED 182
15.19.1 COMPANY OVERVIEW 182
15.19.2 PRODUCT PORTFOLIO 182
15.19.3 RECENT DEVELOPMENTS 182
16 RELATED REPORTS 183